Research programme: prostate cancer therapeutics - PhytoPharmacon
Alternative Names: SP 2011Latest Information Update: 16 Jul 2016
At a glance
- Originator PhytoPharmacon LLC
- Developer PhytoPharmacon
- Class Small molecules
- Mechanism of Action Endothelin receptor antagonists; NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Prostate-cancer in USA
- 29 May 2008 Preclinical trials in Prostate cancer in USA (unspecified route)